Sana Biotechnology Inc
SANA4.225USD
+0.315+8.06%
交易中 （美东）报价延迟15分钟
952.58M总市值
亏损市盈率 TTM
关于 Sana Biotechnology Inc 公司
Sana Biotechnology, Inc. 是一家专注于利用工程细胞作为药物的生物技术公司。该公司致力于开发细胞工程项目，以彻底改变一系列治疗领域尚未得到满足的治疗需求，包括肿瘤学、糖尿病、B 细胞介导的自身免疫和中枢神经系统疾病。该公司开发了一系列临床候选产品，专注于在一系列治疗领域创造变革性的体外疗法。其产品线包括 SC291、SC262、SC255、C379、SC451 和 UP421。该公司正在将其低免疫技术应用于供体来源的 T 细胞，以用作血液系统恶性肿瘤的同种异体细胞疗法。该公司正在开发 SC255，一种 B 细胞成熟抗原导向的同种异体 CAR T，用于治疗多发性骨髓瘤。该公司正在开发 SC262，即其低免疫修饰 CD22 导向的同种异体 CAR T 项目，最初作为复发和/或难治性 B 细胞恶性肿瘤患者的潜在治疗方法。
公司简介
公司代码SANA
公司名称Sana Biotechnology Inc
上市日期Feb 04, 2021
CEOMr. Steven D. (Steve) Harr, M.D.
员工数量194
证券类型Ordinary Share
年结日Feb 04
公司地址188 East Blaine Street, Suite 400
城市SEATTLE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编98102
电话12067017914
网址https://sana.com/
公司代码SANA
上市日期Feb 04, 2021
CEOMr. Steven D. (Steve) Harr, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Steven D. (Steve) Harr, M.D.
Mr. Steven D. (Steve) Harr, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.89M
+0.42%
Mr. Hans Edgar Bishop
Mr. Hans Edgar Bishop
Independent Chairman of the Board
Independent Chairman of the Board
5.83M
+0.13%
Dr. Douglas G. (Doug) Cole, M.D.
Dr. Douglas G. (Doug) Cole, M.D.
Independent Director
Independent Director
202.34K
--
Mr. Patrick Y. Yang
Mr. Patrick Y. Yang
Independent Director
Independent Director
149.25K
--
Mr. Bernard J. (Barney) Cassidy
Mr. Bernard J. (Barney) Cassidy
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
112.99K
--
Dr. Joshua H. (Josh) Bilenker, M.D.
Dr. Joshua H. (Josh) Bilenker, M.D.
Independent Director
Independent Director
20.00K
--
Ms. Mary Agnes (Maggie) Wilderotter
Ms. Mary Agnes (Maggie) Wilderotter
Independent Director
Independent Director
7.11K
--
Mr. Robert Nelsen
Mr. Robert Nelsen
Independent Director
Independent Director
--
--
Dr. Richard Mulligan, Ph.D.
Dr. Richard Mulligan, Ph.D.
Vice Chairman of the Board
Vice Chairman of the Board
--
--
Ms. Michelle R. Seitz
Ms. Michelle R. Seitz
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Steven D. (Steve) Harr, M.D.
Mr. Steven D. (Steve) Harr, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.89M
+0.42%
Mr. Hans Edgar Bishop
Mr. Hans Edgar Bishop
Independent Chairman of the Board
Independent Chairman of the Board
5.83M
+0.13%
Dr. Douglas G. (Doug) Cole, M.D.
Dr. Douglas G. (Doug) Cole, M.D.
Independent Director
Independent Director
202.34K
--
Mr. Patrick Y. Yang
Mr. Patrick Y. Yang
Independent Director
Independent Director
149.25K
--
Mr. Bernard J. (Barney) Cassidy
Mr. Bernard J. (Barney) Cassidy
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
112.99K
--
Dr. Joshua H. (Josh) Bilenker, M.D.
Dr. Joshua H. (Josh) Bilenker, M.D.
Independent Director
Independent Director
20.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月18日 周五
更新时间: 7月18日 周五
持股股东
股东类型
持股股东
持股股东
占比
ARCH Venture Partners
20.33%
Fidelity Management & Research Company LLC
14.96%
Flagship Ventures
11.08%
BlackRock Institutional Trust Company, N.A.
4.56%
Baillie Gifford & Co.
4.52%
Other
44.54%
持股股东
持股股东
占比
ARCH Venture Partners
20.33%
Fidelity Management & Research Company LLC
14.96%
Flagship Ventures
11.08%
BlackRock Institutional Trust Company, N.A.
4.56%
Baillie Gifford & Co.
4.52%
Other
44.54%
股东类型
持股股东
占比
Investment Advisor
34.90%
Venture Capital
32.66%
Individual Investor
8.85%
Investment Advisor/Hedge Fund
7.70%
Hedge Fund
5.71%
Pension Fund
4.72%
Research Firm
1.03%
Bank and Trust
0.20%
Family Office
0.14%
Other
4.09%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
370
216.07M
95.79%
-21.94M
2025Q1
371
221.41M
98.16%
-17.41M
2024Q4
362
230.62M
103.32%
-3.22M
2024Q3
345
226.02M
101.53%
-2.35M
2024Q2
326
221.15M
99.87%
-4.12M
2024Q1
320
217.85M
100.68%
+20.58M
2023Q4
299
191.29M
97.16%
-8.50M
2023Q3
290
194.58M
99.70%
-15.09M
2023Q2
287
203.23M
106.23%
-2.30M
2023Q1
297
197.49M
103.37%
-4.29M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
ARCH Venture Partners
45.86M
20.33%
--
--
Sep 30, 2024
Fidelity Management & Research Company LLC
33.75M
14.96%
+263.25K
+0.79%
Mar 31, 2025
Flagship Ventures
25.00M
11.08%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.28M
4.56%
-101.25K
-0.98%
Mar 31, 2025
Baillie Gifford & Co.
10.19M
4.52%
-42.10K
-0.41%
Mar 31, 2025
CPP Investment Board
10.18M
4.51%
--
--
Mar 31, 2025
Harr (Steven D)
8.89M
3.94%
+37.18K
+0.42%
Mar 31, 2025
The Vanguard Group, Inc.
7.83M
3.47%
-2.88M
-26.90%
Mar 31, 2025
Bishop (Hans Edgar)
5.82M
2.58%
+16.34K
+0.28%
Apr 07, 2025
State Street Global Advisors (US)
5.49M
2.44%
-1.22M
-18.14%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
WisdomTree BioRevolution Fund
1.81%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Global X Genomics & Biotechnology ETF
0.47%
Invesco Nasdaq Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
iShares US Small-Cap Equity Factor ETF
0.06%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.01%
查看更多
WisdomTree BioRevolution Fund
占比1.81%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.97%
Global X Genomics & Biotechnology ETF
占比0.47%
Invesco Nasdaq Biotechnology ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
iShares US Small-Cap Equity Factor ETF
占比0.06%
iShares Biotechnology ETF
占比0.04%
Invesco RAFI US 1500 Small-Mid ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
